Abstract
A full-term, female neonate developed acute hypoxemic respiratory failure complicated by persistent pulmonary hypertension of the newborn (PPHN), and responded to high-frequency oscillatory ventilation (HFOV) and inhaled nitric oxide (iNO). Discontinuation of iNO was attempted three times and was followed by severe desaturation due to right-to-left shunt through the patent ductus arteriosus and patent foramen ovale. As a result of iNO dependency state and rebound pulmonary hypertension, the neonate was maintained on iNO therapy for dipyridamole alone was unsuccessful. However, successful discontinuation of iNO therapy was achieved by combination of L-Arginine and dipyridamole. Exogeous NO may lead to down regulation of endogenous NO production, and further lead to rapid hydrolization of cyclic guanosine 3′, 5′ monophosphate (cGMP), the smooth muscle relaxant, by the enzyme phosphodiesterase. Moreover L-Arginine, the precursor for the formation of endogenous NO, has been found to be deficient in neonates with PPHN,1,2 so we speculated that by inhibiting phosphodiesterase and administrating L-Arginine smooth muscle relaxation occurred, and consequent weaning from iNO was achieved.
Article PDF
References
Vosatka RJ, Kashyap S, Trifiletti R. Arginine deficiency accompanies persistent pulmonay hypertension of the newborn.Biol Neonate 1994; 66 (2–3): 65–70.
Castillo L, De Rojas-Walker T, Yu YMet al. Whole body arginine metabolism and nitric oxide synthesis in newborns with persistent pulmonary hypertension.Pediatric Research 1995; 38 (1): 17–24.
Kinsella JP, Neish SR, Dunbar I, Shaffer E, Abman SH. Cinical responses to prolonged treatment of persistent plumonary hypertension of the newborn with low dose of inhaled nitric oxide.J Pediatr 1993; 123: 103–108.
Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn.Lancet 1992; 340: 818–819.
Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose of inhalational nitric oxide in persistent pulmonary hypertension of the newborn.Lancet 1992; 340: 819–820.
Griffith TM, Edwards DH, Lewis MJ. Evidence that cyclic guanosine monophosphate (cGMP) mediates endothelium-dependent relaxation.Eur J Pharmacol 1985; 112: 195–202.
Al-Alaiyan S, Al-Omran A, Dyer D. The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide.Intensive Care Med 1996; 22: 1093–1095
Bult H, De Meyer GRY, Jordaens FH, Herman AG. Chronic exposure to exogenous nitric oxide may suppress its endogenous release and efficacy.J Cardiovasc Pharmacol 1991; 17 (suppl 3): S79–82.
McCaffrey MJ, Bose CI, Reiter PD, Stiles AD. Effect of L-Arginine infusion on infants with persistent pulmonary hypertension of the newborn.Biol Neonate 1995; 67 (4): 240–243.
Alfonson S, O’ Brien GS. Mechanism of enhancement of adenosine action by dipyridamole and lidoflazine in dogs.Arch Int Pharmacodyn Ther 1971; 194:181–196.
Klabunder RE. Effects of dipyridamole on postischemic vasodilatation extracellular adenosine.Am J Physiol 1983; 224: H273–280.
Scharder JR, Bernc M, Rubio R. Uptake and metabolism of adenosine by human erythrocyte ghosts.Am J Physiol 1973; 223: 159–166.
Beavo JA, Reifsynder. Primary sequences of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors.Trends Pharmacol Sci 1990; 11:150–155.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saidy, K., Al-Alaiyan, S. The use of F-arginine and phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide. Indian J Pediatr 68, 175–177 (2001). https://doi.org/10.1007/BF02722041
Issue Date:
DOI: https://doi.org/10.1007/BF02722041